September marks World Alzheimer’s Month and this year, the Alzheimer’s community is facing more significant challenges than ever.
Nearly 750,000 Canadians are living with Alzheimer’s or another dementia. Due to the significant and prolonged changes brought about by the Coronavirus pandemic, many patients are experiencing increases in symptoms including increased agitation, depression, insomnia and aggressive, and sometimes violent, behaviours.
Current pharmaceutical therapies, including antipsychotic medications, may provide some reduction in behavioural symptoms but carry an increased risk of severe side-effects including stroke and death. As a result, many families are proactively asking for safer alternatives.
There is a growing body of evidence for the use of cannabinoid-based medicines in the treatment of dementia-related symptoms and clinically, we’ve been seeing some outstanding outcomes since beginning therapy. I hope you’ll have a quick watch of this video to learn more.